Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology|September 8, 2021
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical TrialEdmond M Kwan, Lavinia Spain, Angelyn Anton, et al.
The Lancet. Oncology|November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialDaniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Future Oncology (London, England)|June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genesKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Lancet. Oncology|June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
European Urology|December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT TrialShankar Siva, Mathias Bressel, Simon T Wood, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyArun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology|September 8, 2021
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical TrialEdmond M Kwan, Lavinia Spain, Angelyn Anton, et al.
The Lancet. Oncology|November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialDaniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Future Oncology (London, England)|June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genesKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Lancet. Oncology|June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
European Urology|December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT TrialShankar Siva, Mathias Bressel, Simon T Wood, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyArun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Pageof 14